Berubicin
As of the edition of 20 October 2026, Berubicin is a small molecule: stopped in 2025; acts on TOP2A and TOP2B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Small molecule
- Registered trials
- 7, 5 stopped early
- Disease areas
- Cancer; Nervous system; Blood and lymph; Immune system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
6 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product6 company-target rows are on route A because of Berubicin.
See the 6 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 1 | 0 | 3 |
| Phase 2 | 3 | 0 | 1 | 2 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Biogen | Lead sponsor of trials | 2005 to now |
| CNS Pharmaceuticals | Lead sponsor of trials | 2021 to now |
| WPD Pharmaceuticals Sp. z o.o | Lead sponsor of trials | 2022 to now |